Mirizzi syndrome mimicking cholangiocarcinoma. Case report

Gabriel Lorente Mitsumoto,1 Lucas Augusto Monetta da Silva,1 Mauricio Alves Ribeiro,2 Mariana Martins Tocchio,1 Nátalie Emy Yvamoto,1 Talita Di Santi,1 Caroline Petersen da Costa Ferreira,3 Luiz Arnaldo Szutan2

1School of Medicine, Santa Casa de Sao Paulo School of Medical Sciences.
2Department of Surgery, Liver and Portal Hypertension Group, Santa Casa de Sao Paulo School of Medical Sciences.
3Postgraduate from Santa Casa de Sao Paulo School of Medical Science.
Sao Paulo, SP - Brasil.

Summary
Mirizzi syndrome (MS) is a rare condition whose clinical presentation is unspecific, with obstructive jaundice being the most common form. MS is often not recognized at initial presentation, which can result in morbidity and biliary injury. Preoperative diagnosis is uncommon and over 50% of patients with MS are diagnosed during surgery. There are no clinical features to distinguish MS from cholangiocarcinoma, except that patients with cholangiocarcinoma are on average ten years older than patients with MS. We report the case of a 51-year-old female patient who presented with jaundice and weight loss. Following investigation with laboratory and imaging exams, the initial diagnosis was Bismuth II cholangiocarcinoma. The patient underwent surgical intervention, and anatomopathological examination of the specimen showed the correct diagnosis to be MS. Despite the rarity of its incidence, physicians must keep MS in mind as a possible differential diagnosis for cholangiocarcinoma and vice-versa. We discuss this case in the context of a brief review of the literature on Mirizzi syndrome mimicking cholangiocarcinoma.

Key words. Mirizzi syndrome, cholangiocarcinoma, gallstones, biliary tract diseases, biliary obstruction, Roux-en-Y hepaticojejunostomy.

Correspondencia: Mauricio Alves Ribeiro
Rua Mato Grosso, 306 conj. 1311 – CEP 01239 040 São Paulo, SP - Brazil
Tel.: 55 11 99631237
Correo electrónico: mauricio.ribeiro@me.com
diagnóstico diferencial con el colangiocarcinoma y viceversa. Discutimos este caso en el contexto de una breve revisión de la literatura sobre el SM que simula un colangiocarcinoma.

Palabras claves. Síndrome de Mirizzi, colangiocarcinoma, cálculos biliares, enfermedades del tracto biliar, obstrucción biliar, hepaticojejunostomía Roux-en-Y.

Abbreviations
MS: Mirizzi syndrome.
ERCP: Endoscopic retrograde cholangiopancreatography.
CT: Computed tomography.

Introduction
Mirizzi syndrome (MS) was firstly described by Kehr,1 and Ruge,2 in the early 1900s, but it was only in 1948 that Pablo Mirizzi3 fully described this disorder and ultimately provided a name for this uncommon complication of long-standing gallstone disease. MS is a rare condition, with an incidence in patients undergoing biliary surgery varying from 0.7 to 1.4%,4 and is characterized by an acute or chronic inflammatory condition secondary to a single large stone or multiple small gallstones impacted in Hartmann’s pouch or in the gallbladder infundibulum and cystic duct, causing mechanical obstruction of the common hepatic duct.5, 6

The age of MS patients ranges from 53 to 70 years of age with around 70% of cases being in females. Nonetheless, it may occur at any age and in any patient with gallstones.5-7 The clinical presentation of MS is unpecific with obstructive jaundice (60-100%) accompanied by abdominal pain over the right upper abdominal quadrant (50-100%) and fever in the context of a patient with known or suspected gallstone disease being the most commonly presented profile.4-6 Frequently, patients with MS present in the setting of acute cholecystitis, acute cholangitis or acute pancreatitis.4-7 The most common laboratory finding in these patients is hyperbilirubinemia, although high levels of the malignancy marker CA19-9 have also been found in patients with MS.8-11 The diagnosis of MS is based on the clinical characteristics described and a high index of suspicion or surgical intuition, which may be complemented by radiological images and endoscopic procedures, such as ultrasonography, computed tomography (CT), magnetic resonance (MRCP), endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound.6 MS is often not recognized at initial presentation, which can result in morbidity and biliary injury.12 The accurate diagnosis of MS is of particular impor-
A stent was inserted in the biliary tract. An abdominal computed tomography (CT) scan revealed intrahepatic biliary ducts dilation, a hypodense gallbladder with parietal calcifications that may correspond to porcelain gallbladder suggestive of cholangiocarcinoma. (Figure 2 A-E).

The patient was therefore placed on the list for the surgical intervention 1 month after her initial presentation of symptoms and Bismuth type II cholangiocarcinoma diagnosis.

**Figure 2.** *A)* Computed tomography showing the prosthesis in the intra-hepatic biliary tract. *B)* Computed tomography showing the prosthesis exteriorization via the duodenal papilla. *C-E)* Computed tomography of a coronal section showing the prosthesis placed in the biliary tract during ERCP.

The patient’s laboratories exams are listed in Table 1. During surgery, the abdominal cavity was accessed via a J incision, and no secondary peritoneal malignancy was seen.

Fibrosis blocking the gallbladder and its ducts made the dissection difficult. Hepatic hilum dissection and lymphadenectomy were performed until the complete identification of the extrahepatic duct, the portal vein and hepatic artery (Figure 3 A y B). A cholecystectomy was performed, and the extrahepatic duct was resected, retaining the proximal ducts apparent 1 cm below the biliary confluence (Figure 4).
During the operation, frozen section biopsy showed no signs of malignancy at the proximal and distal ducts, only chronic inflammation. The material resected were sent for anatomopathological examination. Roux-en-Y hepaticojejunostomy was performed.

The patient had an uneventful postoperative recovery period and was discharged from hospital. The anatomopathological examination of the specimen collected during surgery confirmed the correct diagnosis of MS.

**Discussion**

This case report is a rare case of Mirizzi syndrome diagnosed postoperatively, appearing as cholangiocarcinoma in the preoperative imaging exams.

The rates of Mirizzi syndrome among patients with symptomatic cholelithiasis are 1-2% according to some studies. However, in low- and middle-income countries, particularly in Latin America, MS is a more common condition with a reported incidence ranging from 4.7-5.7%. A long cystic duct, a cystic duct parallel to

**Table 1. Laboratory exams.**

<table>
<thead>
<tr>
<th></th>
<th>10 days before admittance</th>
<th>Admittance</th>
<th>Reference values $^{27}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin level</td>
<td>12.7</td>
<td>11.4</td>
<td>13.5 - 17.5</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>7.5</td>
<td>3.9</td>
<td>0.20 to 1.20 mg/dL</td>
</tr>
<tr>
<td>Direct bilirubin</td>
<td>5.8</td>
<td>1.0</td>
<td>1.0 mg/dL</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>196</td>
<td>453</td>
<td>40 to 129 U/L</td>
</tr>
<tr>
<td>GGT</td>
<td>1398</td>
<td>1240</td>
<td>12 to 73 U/L</td>
</tr>
</tbody>
</table>

**Figure 3.** A) Intraoperative view showing hepatic artery, common hepatic duct, portal vein and gallbladder. B) Intraoperative view showing hepatic artery, common hepatic duct and portal vein.

**Figure 4.** Gallbladder open to the biliary duct.

During the operation, frozen section biopsy showed no signs of malignancy at the proximal and distal ducts, only chronic inflammation. The material resected were sent for anatomopathological examination. Roux-en-Y hepaticojejunostomy was performed.
the bile duct, and a low insertion of the cystic duct into the bile duct, have been regarded as predisposing factors for the development of MS. In this case, the patient presented symptoms of Bismuth type II cholangiocarcinoma, such as obstructive jaundice and weight loss.

The incidence rate of the different types of MS according to Beltrán and Csendes are the following: Mirizzi type I is (the most common) 10.5-78%, Mirizzi II 15-41%, Mirizzi III 3-44%, and Mirizzi IV 1-4%. Mirizzi V (which includes the presence of a cholecystoenteric fistula together with any other type of Mirizzi) can be present in up to 29% of patients.

The differential diagnosis of MS includes any other benign or malignant cause of obstructive jaundice, such as gallbladder cancer, cholangiocarcinoma, pancreatic cancer, sclerosing cholangitis, or metastatic disease.

Preoperative diagnosis of MS, although ideal, it is not always possible, being reported to occur in 8-62.5% of patients. In intent to perform preoperative diagnosis, abdominal ultrasound is the initial exam. Computed tomography, MRCP and ERCP are complementary exams. Abdominal ultrasound, which has a sensitivity of 8.3-27%, generally shows cholelithiasis with impacted gallstone in Hartmann’s pouch or in the gallbladder infundibulum, contracted gallbladder and biliary ducts dilation.

Abdominal CT does not have specific radiological features for MS, but this technique can be very effective in detecting the cause and location of biliary obstruction. It also may either exclude neoplastic lesions or suggest them in the presence of lymph node enlargement, hepatic infiltration or metastasis.

MRCP is a valuable method to study the biliary tract, with an accuracy of 50% for the diagnosis of MS. Using image weighted in T2 it is possible to differentiate between inflammatory (characteristic of MS) and neoplastic process, which may not be possible using ultrasound or CT.

ERCP, modality of image exam with the most sensitivity, has an accuracy of 50-100%, performing the diagnosis of cholecystobiliary fistula and, when associated with sphincterotomy, allows for biliary decompression and prosthesis placement in patients with obstructive jaundice and cholangitis. In the case reported, the patient underwent ERCP, hence a biliary tract study was already performed, thus MRCP was found unnecessary.

There are a few cases reported in the literature about using echoendoscopy/endoscopic ultrasound in the diagnosis of MS. The findings using this type of exam that suggest MS are a hypoechoic multilaminated structure with internal calcification at the cystic duct region, and common hepatic duct dilation. Goméz and Meneses, 21 reported two cases of MS with the diagnosis made from echoendoscopy, proposing this exam as the gold-standard for this disease. In our view, echoendoscopy is another valuable exam, but generally the patients are admitted at the emergency department, and this is not an easily accessible exam in this context. Furthermore, echoendoscopy is usually used for staging when malignancy is suspected.

If a preoperative diagnosis is not made, intraoperative recognition and proper management is essential. Inadequate recognition of this condition leads to high preoperative morbidity and mortality. Our patient was a postoperative diagnosis, made through anatomopathological examination, but in the intraoperative we also had this suspicion.

Surgery is the primary treatment choice for MS. Distorted biliary anatomy with increased risk of bile duct injury poses a daunting surgical challenge, given that the correct preoperative diagnosis is uncommon, and over 50% of patients with MS are diagnosed during surgery. In patients who are not surgical candidates, endoscopic or percutaneous biliary decompression may be the initial treatment.

There are no clinical features to distinguish MS from cholangiocarcinoma, except that patients with cholangiocarcinoma are on average ten years older than patients with MS alone. It must be kept in mind that high levels of CA19-9 have been found in some patients with MS.

Despite the first suspicion of cholangiocarcinoma, the profile of this case report was similar to MS. The incidence of carcinoma is highest in older patients (60-70 years old), while our patient was 51 years old. MS is more prevalent in woman, as in this case. However, the clinical and imaging exams were more suggestive of carcinoma, such as a consumptive syndrome or porcelain gallbladder at CT.

For the literature review we searched the PubMed database for articles published up to June 2018 using the terms “Mirizzi”, “syndrome” and “cholangiocarcinoma”. We identified 17 articles. The abstracts of the articles were evaluated, and only six of them involved cases of MS appearing as cholangiocarcinoma (Table 2).

Our case is similar to some of those in the literature, in which the correct diagnosis of MS was not made preoperatively (Table 2). The findings of (I) a scleratrophic gallbladder, (II) fibrotic regions blocking the gallbladder and its ducts, and (III) negative results from the frozen section biopsy, led to the correct diagnosis.
Table 2. Reported cases.

<table>
<thead>
<tr>
<th>Author</th>
<th>Age</th>
<th>Ca 19-9 (U/mL)</th>
<th>Image that suggested cholangiocarcinoma</th>
<th>Time of diagnosis of MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Principe et al.²⁸</td>
<td>-</td>
<td>35.000</td>
<td>ERCP</td>
<td>Intraoperatively</td>
</tr>
<tr>
<td>Sanchez et al.⁹</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Intraoperatively</td>
</tr>
<tr>
<td>Khalid and Bhatti¹⁴</td>
<td>50</td>
<td>-</td>
<td>Ultrasonography</td>
<td>Preoperatively</td>
</tr>
<tr>
<td>Robertson¹⁰</td>
<td>71</td>
<td>16.785</td>
<td>CT scan, MRCP and ERCP</td>
<td>Intraoperatively</td>
</tr>
<tr>
<td>Gibor et al.¹¹</td>
<td>68</td>
<td>3.145</td>
<td>CT scan, MRCP and ERCP</td>
<td>Postoperatively</td>
</tr>
<tr>
<td>Gluskin and Komanduri²⁸</td>
<td>72</td>
<td>-</td>
<td>ERCP</td>
<td>Preoperatively</td>
</tr>
</tbody>
</table>

MRCP: magnetic resonance cholangiopancreatogram.

Conclusion

In summary, the rarity of MS and the lack of particular clinical features make it easy for it to be misdiagnosed as cholangiocarcinoma. This precise diagnosis was challenging since the disease mimicked the clinical presentation and images of a cholangiocarcinoma, even intraoperatively, and required anatomopathological study to confirm the diagnosis. Hence, despite the rarity of its incidence, physicians must keep in mind that MS can be a differential diagnosis for cholangiocarcinoma and vice versa.

Conflicts of interest. None to declare.

Source of funding. None.

References